CINECA IRIS Institutional Research Information System

VIVALDI, CATERINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.651
AS - Asia 4.998
EU - Europa 3.182
SA - Sud America 972
AF - Africa 415
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 1
Totale 18.238
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.433
SG - Singapore 1.807
CN - Cina 1.207
IT - Italia 974
BR - Brasile 792
HK - Hong Kong 714
SE - Svezia 529
VN - Vietnam 508
DE - Germania 354
GB - Regno Unito 275
CI - Costa d'Avorio 221
FR - Francia 198
BG - Bulgaria 180
RU - Federazione Russa 159
FI - Finlandia 126
CA - Canada 122
JP - Giappone 120
AT - Austria 119
IN - India 119
TR - Turchia 93
BD - Bangladesh 80
AR - Argentina 72
KR - Corea 72
NL - Olanda 62
SN - Senegal 60
IQ - Iraq 58
PL - Polonia 47
MX - Messico 42
ES - Italia 33
ID - Indonesia 33
PK - Pakistan 32
NG - Nigeria 31
EC - Ecuador 29
UA - Ucraina 29
ZA - Sudafrica 25
MA - Marocco 23
VE - Venezuela 23
UZ - Uzbekistan 22
SA - Arabia Saudita 17
LT - Lituania 16
CO - Colombia 15
AU - Australia 14
MY - Malesia 13
KE - Kenya 12
TN - Tunisia 12
CL - Cile 11
CZ - Repubblica Ceca 10
PE - Perù 10
AE - Emirati Arabi Uniti 9
CH - Svizzera 9
EG - Egitto 9
IR - Iran 9
JM - Giamaica 9
JO - Giordania 9
PA - Panama 9
PH - Filippine 9
PY - Paraguay 9
RO - Romania 9
IE - Irlanda 8
LB - Libano 8
BE - Belgio 7
UY - Uruguay 7
CR - Costa Rica 6
DZ - Algeria 6
IL - Israele 6
NP - Nepal 6
HN - Honduras 5
HU - Ungheria 5
PS - Palestinian Territory 5
SV - El Salvador 5
TT - Trinidad e Tobago 5
TW - Taiwan 5
AL - Albania 4
AO - Angola 4
AZ - Azerbaigian 4
BO - Bolivia 4
DO - Repubblica Dominicana 4
ET - Etiopia 4
NZ - Nuova Zelanda 4
PT - Portogallo 4
TH - Thailandia 4
EE - Estonia 3
KG - Kirghizistan 3
KH - Cambogia 3
LV - Lettonia 3
OM - Oman 3
SK - Slovacchia (Repubblica Slovacca) 3
SY - Repubblica araba siriana 3
AM - Armenia 2
BB - Barbados 2
BH - Bahrain 2
BJ - Benin 2
BY - Bielorussia 2
GD - Grenada 2
GE - Georgia 2
GR - Grecia 2
KZ - Kazakistan 2
LU - Lussemburgo 2
MD - Moldavia 2
MM - Myanmar 2
Totale 18.208
Salva come PNG Salva come JPEG
Città #
Ashburn 1.123
Singapore 988
Hong Kong 702
San Jose 651
Santa Clara 631
Woodbridge 520
Dallas 462
Fairfield 450
Chandler 449
Houston 362
Ann Arbor 336
Shanghai 298
New York 241
Abidjan 221
Los Angeles 212
Beijing 202
Seattle 184
Wilmington 183
Sofia 179
Boardman 167
Cambridge 165
Milan 137
Ho Chi Minh City 132
Council Bluffs 122
Princeton 117
London 116
Florence 113
Munich 108
Tokyo 104
Lawrence 103
Hefei 99
Lauterbourg 98
Hanoi 96
Vienna 92
Pisa 90
Medford 77
Buffalo 67
Frankfurt am Main 66
Istanbul 61
Dakar 60
Seoul 60
Ottawa 57
São Paulo 51
Serra 50
Redondo Beach 49
San Diego 49
Helsinki 47
Düsseldorf 38
Turku 36
Warsaw 36
Des Moines 35
Rome 34
Nuremberg 32
Fuzhou 31
Baghdad 30
Lancaster 30
Da Nang 29
Orem 29
Lagos 28
Bremen 27
Ogden 27
Dearborn 26
Kent 26
Nanjing 26
Phoenix 25
Denver 24
Cascina 22
Chicago 21
Hyderabad 21
Curitiba 20
Haiphong 20
Chennai 19
Tashkent 19
Colorado Springs 18
Memphis 18
Montreal 18
Poplar 17
Stockholm 17
Dong Ket 16
Hebei 16
Quanzhou 16
Rio de Janeiro 16
Toronto 16
Boston 15
Mexico City 15
Brooklyn 14
Lappeenranta 14
Norwalk 14
Seacroft 14
Belo Horizonte 13
Manchester 13
Changsha 12
Guangzhou 12
Lucca 12
Porto Alegre 12
Quito 12
San Francisco 12
Vicopisano 12
Brasília 11
Dhaka 11
Totale 12.044
Salva come PNG Salva come JPEG
Nome #
PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC 324
Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer 219
Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer 199
Zebrafish patient-derived xenografts identify chemo-response in pancreatic ductal adenocarcinoma patients 198
The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer 194
In Pancreatic Adenocarcinoma Alpha-Synuclein Increases and Marks Peri-Neural Infiltration 192
HER2 overexpression as a poor prognostic determinant in resected biliary tract cancer 187
Is there a role for palliative gastrectomy in asymptomatic metastatic gastric cancer? 184
EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas 182
Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients 181
Second-line therapy for advanced pancreatic cancer: Evaluation of prognostic factors and review of current literature 176
First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors 176
Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Cohort Study 175
Tumor regression grade (TRG) evaluation of 29 borderline/locally advanced pancreatic cancers (LAPCs) after neoadjuvant chemotherapy (NACT) using different pathological scores: a clinical and prognostic correlation 173
Primary Resistance to Immunotherapy-Based Regimens in First Line Hepatocellular Carcinoma: Perspectives on Jumping the Hurdle 172
Correlation between LDH levels and response to sorafenib in HCC patients: An analysis of the ITA.LI.CA database 170
Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment. 170
Topoisomerase 1 promoter variants and benefit from irinotecan in metastatic colorectal cancer patients 169
Tolerability of FOLFOXIRI regimen after surgical resection for pancreatic cancer. 166
EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected adenocarcinomas of the stomach and gastro-esophageal junction 162
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel 161
Detailing the ultrastructure’s increase of prion protein in pancreatic adenocarcinoma 161
Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy. 159
Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data 159
Gemcitabine plus nab-paclitaxel induces PD-L1 mRNA expression in plasma-derived microvesicles in pancreatic cancer 159
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). 155
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 155
Multicenter Prospective Study of Angiogenesis Polymorphism Validation in HCC Patients Treated with Sorafenib. An INNOVATE Study Protocol 153
Immune checkpoint inhibitors in esophageal cancers: Are we finally finding the right path in the mist? 153
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib 151
First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age? 151
Prognostic model for patients (PTS) with advanced pancreatic cancer (aPC) receiving first-line modified FOLFIRINOX (Mfolfirinox) 147
Single-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine: The Experience of the Italian Association of Neuro-Oncology 146
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: A survey of young oncologists 146
Prognostic value of CD133 caused by mutant K-Ras and B-Raf 145
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. 142
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma 141
Stereotactic Body Radiotherapy in Patients with Lung Oligometastases from Colorectal Cancer 141
Role of Baseline Computed-Tomography-Evaluated Body Composition in Predicting Outcome and Toxicity from First-Line Therapy in Advanced Gastric Cancer Patients 141
Second-line chemotherapy (CT2) in advanced biliary tract cancer (aBTC) patients (PTS) progressed to first-line chemotherapy (CT1) with gemcitabine plus platinum: where are we now? 139
Neuroendocrine Liver Metastases 139
Abdominal Visceral-to-Subcutaneous Fat Volume Ratio Predicts Survival and Response to First-Line Palliative Chemotherapy in Patients with Advanced Gastric Cancer 138
Comment on: 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: An AGEO prospective multicentre cohort' 138
A multicenter, randomized phase III study of second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (MCRC) patients who progressed to a first-line treatment containing bv: results from the bebyp trial by the Gruppo Oncologico Nord Ovest (GONO). 138
Baseline computed-tomography (CT)-evaluated sarcopenia predicts toxicity from first-line chemotherapy in metastatic gastric cancer (mGC) patients 138
Folfoxiri in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). 137
Minor-but-Complex Liver Resection: An Alternative to Major Resections for Colorectal Liver Metastases Involving the Hepato-Caval Confluence. 136
Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer. 136
Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan 136
Feasibility of BRCA1/2 testing of formalin-fixed and paraffin-embedded pancreatic tumor samples: A consecutive clinical series 136
Robotic Versus Open Pancreatoduodenectomy With Vein Resection and Reconstruction: A Propensity Score-Matched Analysis 135
Dynamic profiling of the immune tumor microenvironment in locally advanced gastric cancer treated with perioperative chemotherapy 135
Factors predicting survival in patients with locally advanced pancreatic cancer undergoing pancreatectomy with arterial resection 135
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 134
Bevacizumab in the pre-operative treatment of locally advanced rectal cancer: A systematic review. 134
Association of NOS3 and ANGPT2 gene polymorphisms with survival in patients with hepatocellular carcinoma receiving sorafenib: Results of the multicenter prospective INNOVATE study 134
Palliative gastrectomy in asymptomatic metastatic esophagogastric cancer (EGC): does it make sense? 133
Multimodality treatment of locally advanced squamous cell carcinoma of the oesophagus: A comprehensive review and network meta-analysis 133
Not only chemotherapy in the second-line treatment of metastatic gastric cancer. 131
Prognostic relevance of a T-type calcium channels gene signature in solid tumours: A correlation ready for clinical validation 131
Prognostic value of CD133 caused by mutant K-RAS and B-RAF letter. 130
Pharmacoepigenetics in gastrointestinal tumors: MGMT methylation and beyond 129
Locally advanced gastro-oesophageal cancer: Recent therapeutic advances and research directions 129
Erratum to: Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy (The Oncologist, (2017), 22, 12, (1463-1469), 10.1634/theoncologist.2017-0158) 129
Functional characterization of EZH2 single nucleotide polymorphism and correlation of EZH2 expression with clinico-pathological and molecular parameters in colorectal (CRC) cancer samples. 127
Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study 127
Resectable liver metastases from colorectal cancer: where we are now and where do we go from here? 125
Predictive significance of circulating histones in hepatocellular carcinoma patients treated with sorafenib 124
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab 123
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 121
Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancer 120
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data 120
Tumor Regression Grading Assessment in Locally Advanced Pancreatic Cancer After Neoadjuvant FOLFIRINOX: Interobserver Agreement and Prognostic Implications 120
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 119
Mismatch Repair Deficiency in Biliary Tract Cancer: Prognostic Implications and Correlation with Histology 119
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population 118
FLOaTing toward new standards in locally advanced resectable gastroesophageal cancer 118
Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma 118
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 118
Cholangiocarcinoma: new perspectives for new horizons 117
Regorafenib: lights and shadows of antiangiogenic therapies in gastric cancer 116
Single-centre experience with third-line chemotherapy with irinotecan plus 5-fluorouracil and leucovorin (FOLFIRI) in metastatic gastric cancer patients. 116
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma 115
Moving beyond sorafenib alone in advanced hepatocellular carcinoma: Is hepatic arterial infusion chemotherapy the best option? 115
Glycolytic competence in gastric adenocarcinomas negatively impacts survival outcomes of patients treated with salvage paclitaxel-ramucirumab 115
A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy 113
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 112
Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index 111
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations 110
Assessment of radiation sensitivity of unresectable intrahepatic cholangiocarcinoma in a series of patients submitted to radioembolization with yttrium-90 resin microspheres 109
Selecting patients for gastrectomy in metastatic esophago-gastric cancer: Clinics and pathology are not enough 109
FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules 107
Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience 107
Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer 107
Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis 105
Primary Tumor Resection for Metastatic Colorectal, Gastric and Pancreatic Cancer Patients: In Search of Scientific Evidence to Inform Clinical Practice 105
Yttrium-90 Radioembolization in Unresectable Intrahepatic Cholangiocarcinoma: Results of a Multicenter Retrospective Study 104
The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib 104
Effects of Metformin and Vitamin D on Clinical Outcome in Cholangiocarcinoma Patients 103
Long-term survival after liver metastasectomy in gastric cancer: Systematic review and meta-analysis of prognostic factors 102
Totale 14.117
Salva come PNG Salva come JPEG
Categoria #
all - tutte 64.360
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 64.360
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.030 14 20 17 27 171 217 30 35 67 81 90 261
2022/20231.863 186 280 154 93 177 206 15 128 450 7 141 26
2023/20241.209 73 96 144 54 161 171 154 47 37 41 90 141
2024/20254.850 28 199 90 236 443 677 370 197 495 550 616 949
2025/20266.478 500 733 631 684 741 479 935 352 357 615 308 143
2026/202754 54 0 0 0 0 0 0 0 0 0 0 0
Totale 18.610